Streetbeat News

TSVT

2seventy bio, Inc.

https://www.2seventybio.com

Industry

Biotechnology

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Open

3.41

Mkt cap

171M

Volume

141K

High

3.41

P/E Ratio

-1.09

52-wk high

6.40

Low

3.25

Div yield

N/A

52-wk low

1.53

2seventy bio plans to conserve over $80 million in near-term expenditures by making a decision on the KarMMa-9 study. This move is expected to accelerate the company's path to breakeven by 2025.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:04 am

2seventy bio and Bristol Myers Squibb have decided to discontinue enrollment in the Phase 3 KarMMa-9 study due to improvements in the NDMM treatment landscape and a review of the business case.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 10:03 am

2seventy Bio shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:51 pm

2seventy bio (NASDAQ:TSVT) reported Q2 2024 adjusted EPS of $(0.29), beating the estimate of $(0.65). However, sales of $8.967M missed the $14.195M estimate and were down 75.12% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:45 am

Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 4:30 pm

Novo Nordisk has acquired 2seventy Bio's Hemophilia A program and related gene editing technology. 2seventy Bio will now focus exclusively on its CAR T cell therapy, Abecma, in collaboration with Bristol Myers Squibb. The deal could bring up to $40 million to 2seventy Bio.

Portfolio Pulse from Vandana Singh

June 27, 2024 | 5:17 pm

Wedbush analyst David Nierengarten has reiterated a Neutral rating on 2seventy bio (NASDAQ:TSVT) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:41 pm

2seventy Bio shares are trading higher after the company announced the sale of its Hemophilia A candidate and MegaTAL to Novo Nordisk.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:12 pm

2seventy Bio has sold its Hemophilia A candidate and MegaTAL in vivo gene editing technology to Novo Nordisk for up to $40 million. This divestiture will allow 2seventy Bio to focus on the development and commercialization of Abecma.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:12 pm

Canaccord Genuity analyst John Newman maintains a Buy rating on 2seventy bio (NASDAQ:TSVT) but lowers the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.